1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 234 results for "Multiple Myeloma (MM)".

MM - 579

Ionized Calcium Outperforms Corrected Calcium for Hypercalcemia Assessment in Multiple Myeloma

Mario Alberto Ochoa Rodriguez

Poster Presenter: Mario Alberto Ochoa Rodriguez

$Thumbnail for Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3$

MM - 593

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Omik Patel

Poster Presenter: Omik Patel

SOHO 2026 Annual Meeting

Topics

Ionized Calcium Outperforms Corrected Calcium for Hypercalcemia Assessment in Multiple Myeloma

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Post-BCMA Sequencing in Relapsed/Refractory Multiple Myeloma: BCMA Re-Targeting Versus Non-BCMA T-Cell Redirection

Treatment Selection and Sequencing Preferences for Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Comparative Survey of Advanced Practice Providers and Physicians

Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study

Expression Levels of lncRNA DANCR and lncRNA MIR17HG in Patients with Multiple Myeloma: Relation to Disease Characteristics and Other Prognostic Markers.

GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation

Treatment of high-risk smoldering multiple myeloma (HRSMM) with Isatuximab, lenalidomide, oral Cyclophosphamide and Dexamethasone: a survival advantage

Primary Prophylaxis With Immunoglobulin Replacement Therapy Is Associated With Lower Cumulative Infection Burden and Healthcare Utilization in Patients With Multiple Myeloma Receiving BCMA-Directed BsAbs